期刊文献+

前列腺癌筛查对高危人群的效果评价

下载PDF
导出
摘要 目的探讨前列腺癌筛查对高危人群的效果评价。方法选择2020年1月至2022年12月诸暨市前列腺癌筛查基地(筛查组)和诸暨市人民医院(门诊组)收治的行前列腺穿刺活检患者562例。比较筛查组和门诊组患者前列腺癌阳性率及危险因素。结果筛查组和门诊组患者前列腺癌阳性率比较,差异无统计学意义(χ^(2)=3.038,P=0.081)。筛查组高危前列腺癌检出率低于门诊组(P<0.05)。两组确诊前列腺癌患者的PSA水平、Gleason评分和临床分期比较,差异有统计学意义(P<0.05)。结论针对高危人群的前列腺癌筛查,可以有效提高低危、中危前列腺癌患者的检出率。加强PSA异常患者的健康宣教工作,有利于前列腺癌筛查工作的顺利开展。 Objective To evaluate the effect of prostate cancer screening in high-risk groups.Methods A total of 582 patients over 60 years old with serum PSA>4μg/L were selected from prostate cancer screening bases(screening group)in Zhuji City,Zhejiang Province and Zhuji People's Hospital(outpatient group)from January 2020 to December 2022 for prostate biopsy.The positive rate of prostate cancer and the risk factors of prostate cancer were compared between the screening group and the outpatient group.Results Comparison of prostate cancer positivity rates between patients in the screening and outpatient groups showed no statistically significant difference(χ^(2)=3.038,P=0.081).The detection rate of high-risk prostate cancer in screening group was significantly lower than that in outpatient group(P<0.05).Comparison of PSA levels,Gleason scores and clinical stages of patients diagnosed with prostate cancer in the two groups showed statistically significant differences(P<0.05).Conclusion Screening for prostate cancer in high-risk groups can effectively improve the detection rate of low-risk and medium-risk prostate cancer patients.Strengthening the health education for patients with abnormal PSA is conducive to the smooth development of prostate cancer screening.
出处 《浙江临床医学》 2024年第8期1170-1171,1174,共3页 Zhejiang Clinical Medical Journal
基金 绍兴市级医卫类科技计划项目(2020A13085)。
关键词 前列腺癌筛查 前列腺特异性抗原 前列腺穿刺 Prostate cancer screening Prostate-specific antigen Prostatic puncture
  • 相关文献

参考文献8

二级参考文献92

  • 1艾尔肯,秦永志.论医疗知情同意书——兼评《侵权责任法》第55条、第56条的规定[J].东方法学,2010(3):109-115. 被引量:21
  • 2邵常霞,项永兵,刘振伟,高静,孙璐,方茹蓉,阮志贤,高立峰,金凡,高玉堂.上海市区泌尿系统恶性肿瘤相对生存率分析[J].中国肿瘤临床,2005,32(6):321-324. 被引量:31
  • 3Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin, 2005, 55:74-108.
  • 4Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin, 2006, 56:106-130.
  • 5Michael PM, Bernard D, Kaill M, et al. Management of prostate cancer in China: a multicenter report of 6 institutions. J Urol, 2005, 174:1794-1797.
  • 6Murphy AM, McKiernan JM, Olsson CA. Controversies in prostate cancer screening. J Urol, 2004, 172 : 1822-1827.
  • 7Benaim EA, Pace CM, Roehrbor CG. Gleason score predicts androgen independent progression after androgen deprivation therapy. Eur Urel, 2002, 42:12-17.
  • 8Benaim EA, Pace CM, Lam PM, et al. Nadir PSA as a progression to androgeindependent prostate cancer. Urology, 2002, 59:73-77.
  • 9Siddall JK, Hetherington JW, Cooper EH, et al. Biochemical monitoring of carcinoma of prostate treated with an LRH analogue (Zoladex). Br J Urol, 1986, 58:676-679.
  • 10Mulders PF, Fernandez del MP, Theeuwes AG, et al. Value of biochemical markers in the management of disseminated prostatic cancer. Eur Urol, 1992, 21:2-7.

共引文献1754

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部